Multiple Sclerosis (MS) TYSABRI is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis to delay the accumulation of physical disability and reduce the frequency of clinical exacerbations. The efficacy of TYSABRI beyond two years is unknown. Crohn’s Disease (CD) TYSABRI is indicated for Inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn’s disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF-α.

What is Tysabri (natalizumab) used for?

TYSABRI is a prescription medicine approved for: 1. Adult patients with relapsing forms of Multiple Sclerosis (MS) and 2. Adult patients with moderate to severe Crohn’s disease...

Where can I buy Tysabri?

Indian Pharma Network (IPN) is a supplier & wholesaler. Expertise in Specialty Pharmaceutical distribution having its presence PAN India with over 20 years of domain experience. IPN is your facilitator under Patient Assistance Programs.

Please contact +91 9811747774 for
Tysabri cost in India or natalizumab price in in India.
TYSABRI (natalizumab)

Get In Touch

Tysabri suppliers & wholesalers in India

Head Office of Indian Pharma Network (IPN) is in New Delhi, INDIA.
For Indian Patients Tysabri can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow and Pune and other cities in India.
For overseas patient Tysabri or natalizumab brands in India can be also made available to overseas patients, doctors and hospitals. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Dosage Forms and Strengths

300 mg infused intravenously over approximately one hour, every four weeks. Do not give as an intravenous push or bolus.


News Release

Good News for Tysabri Users Who Are JCV Positive.
Dated: FEBRUARY 9, 2018